Drug intelligence / Profile preview

V010

Development stage: Preclinical
Lead developer: Changzhou Siyao Pharmaceuticals
Modality: Cell Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

V010 is a proprietary research project and therapeutic platform under development by Changzhou Siyao Pharmaceuticals in collaboration with the Changzhou Siyao Israel Biological Research Institute (常州四药中以生物研究院). Described as an industry-first platform, V010 integrates cell therapy and gene therapy technologies to facilitate the development of novel biological macromolecule drugs. While specific molecular targets and clinical phases have not been publicly disclosed, the project is part of the company's strategic focus on high-end biological innovation in therapeutic areas such as cardiovascular diseases, gynecology, and neurodegenerative disorders.

Beyond the preview

Go deeper on V010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V010.

Explore the full profile